Page last updated: 2024-09-05

paromomycin and Disease Models, Animal

paromomycin has been researched along with Disease Models, Animal in 35 studies

Research

Studies (35)

Timeframe	Studies, this research(%)	All Research%
pre-1990	4 (11.43)	18.7374
1990's	8 (22.86)	18.2507
2000's	7 (20.00)	29.6817
2010's	16 (45.71)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Chong, CR; Downey, AS; Graczyk, TK; Sullivan, DJ	1
Boykin, DW; Hall, JE; Kyle, DE; Liu, Q; Madhubala, R; Mandal, S; Munde, M; Pandharkar, T; Parman, T; Riccio, E; Srivastava, A; Stephens, CE; Sweat, JM; Tidwell, RR; Wang, MZ; Werbovetz, KA; Wilson, WD; Zhu, X	1
Croft, SL; Murdan, S; Van Bocxlaer, K; Wijnant, GJ; Yardley, V	1
Asadpour, M; Namazi, F; Nazifi, S; Razavi, SM	2
Blanco, L; Calvo, A; Espuelas, S; Fernández-Rubio, C; Irache, JM; Larrea, E; Moreno, E; Nguewa, P; Sanmartín, C; Schwartz, J	1
Adjou, KT; Auclair, E; Chevillot, A; Julien, C; Mammeri, M; Marden, JP; Polack, B; Thomas, M; Vallée, I	1
Cos, P; Delputte, P; Eberhardt, E; Hendrickx, S; Maes, L; Mondelaers, A	1
Calado, S; Castro, H; Correia, I; Cruz, ME; Ferronha, H; Gaspar, MM; Pereira, J; Tomás, AM	1
Abu-Kishk, I; Berkovitch, M; El-On, Y; Livneh, A; Youngster, I	1
Aguiar, MG; de Morais-Teixeira, E; Ferreira, LA; Rabello, A; Soares de Souza Lima, B	1
Doroud, D; Habibzadeh, S; Heidari-Kharaji, M; Rafati, S; Taheri, T	1
Beyers, J; Cos, P; Delputte, P; Eberhardt, E; Hendrickx, S; Lachaud, L; Maes, L; Mondelaers, A	1
Badirzadeh, A; Doroud, D; Habibzadeh, S; Heidari-Kharaji, M; Rafati, S; Taheri, T	1
Ellis, CD; Gregory-Evans, CY; Gregory-Evans, K; Moosajee, M; Seabra, MC	1
Aguiar, MG; Fernandes, AP; Ferreira, LA; Nunan, EA; Nunan, FA; Silva, DL	1
Gupta, S; Sane, SA; Shakya, N	1
Böttger, EC; Brun, R; Hobbie, SN; Janusic, T; Kaiser, M; Schmidt, S; Shcherbakov, D	1
Bavarsad, N; Fazly Bazzaz, BS; Jaafari, MR; Khamesipour, A	1
Agnamey, P; Ballet, JJ; Brasseur, P; Favennec, L; Leméteil, D; Li, X; Rossignol, JF	1
Buggiani, C; Fichi, G; Flamini, G; Perrucci, S; Rossi, G	1
Al-Malki, JS; Sanad, MM	1
Hayashi, S; Kamo, H	1
Hayashi, S; Kagei, N; Kato, K; Umeki, F	1
Rand, W; Theodos, C; Tzipori, S	1
Rehg, JE	1
Garry, L; Gaudebout, C; Marche, C; Pocidalo, JJ; Polianski, J; Verdon, R	1
Ellis, W; Fayer, R	1
Crabb, J; Griffiths, J; Rand, W; Tzipori, S; Widmer, G	1
Derouin, F; Gangneux, JP; Garin, YJ; Sulahian, A	1
Baillie, AJ; Carter, KC; Mullen, AB; Williams, D	1
Carvalho, FA; Castro, GA; Fernandes, AP; Ferreira, LA; Gazzinelli, RT; Santiago, HC; Tafuri, WL; Tavares, CA	1
el-On, J; Elias, E; Sneier, R	1
Conroy, J; Cuckler, AC; Malanga, CM	1
Bass, P; Clinger, WA; Varner, P; Wax, J; Winder, CV	1

Trials

1 trial(s) available for paromomycin and Disease Models, Animal

Article	Year
[Studies on the effect and the mode of action of paromomycin sulfate against tapeworm]. The Japanese journal of antibiotics, 1983, Volume: 36, Issue:3 Topics: Adolescent; Adult; Aged; Animals; Cestoda; Cestode Infections; Child; Child, Preschool; Clinical Trials as Topic; Cricetinae; Diphyllobothriasis; Disease Models, Animal; Drug Evaluation, Preclinical; Female; Humans; Infant; Japan; Male; Mice; Middle Aged; Paromomycin	1983

Article

Year

[Studies on the effect and the mode of action of paromomycin sulfate against tapeworm].

The Japanese journal of antibiotics, 1983, Volume: 36, Issue:3

Topics: Adolescent; Adult; Aged; Animals; Cestoda; Cestode Infections; Child; Child, Preschool; Clinical Trials as Topic; Cricetinae; Diphyllobothriasis; Disease Models, Animal; Drug Evaluation, Preclinical; Female; Humans; Infant; Japan; Male; Mice; Middle Aged; Paromomycin

1983

Other Studies

34 other study(ies) available for paromomycin and Disease Models, Animal

Article	Year
Efficacy of pyrvinium pamoate against Cryptosporidium parvum infection in vitro and in a neonatal mouse model. Antimicrobial agents and chemotherapy, 2008, Volume: 52, Issue:9 Topics: Animals; Animals, Newborn; Antiprotozoal Agents; Cell Line; Cryptosporidiosis; Cryptosporidium parvum; Disease Models, Animal; Dose-Response Relationship, Drug; Humans; Mice; Mice, Inbred BALB C; Pyrvinium Compounds; Treatment Outcome	2008
Novel arylimidamides for treatment of visceral leishmaniasis. Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:6 Topics: Amidines; Animals; Antiprotozoal Agents; Biological Availability; Cricetinae; Disease Models, Animal; Drug Discovery; Female; Furans; Humans; In Vitro Techniques; Leishmania donovani; Leishmania major; Leishmania mexicana; Leishmaniasis, Visceral; Liver; Mesocricetus; Mice; Mice, Inbred BALB C; Microsomes, Liver; Mutagenicity Tests; Parasitemia; Parasitic Sensitivity Tests; Spleen; Tissue Distribution	2010
Efficacy of Paromomycin-Chloroquine Combination Therapy in Experimental Cutaneous Leishmaniasis. Antimicrobial agents and chemotherapy, 2017, Volume: 61, Issue:8 Topics: Amphotericin B; Animals; Antiprotozoal Agents; Chloroquine; Disease Models, Animal; Drug Combinations; Female; Leishmania major; Leishmania mexicana; Leishmaniasis, Cutaneous; Mice; Mice, Inbred BALB C; Parasite Load; Parasitic Sensitivity Tests; Paromomycin; Phosphorylcholine	2017
Comparative efficacy of curcumin and paromomycin against Cryptosporidium parvum infection in a BALB/c model. Veterinary parasitology, 2018, Jan-30, Volume: 250 Topics: Animals; Cryptosporidiosis; Cryptosporidium parvum; Curcumin; Disease Models, Animal; Feces; Female; Intestine, Small; Mice; Mice, Inbred BALB C; Oocysts; Paromomycin	2018
Combination of paromomycin plus human anti-TNF-α antibodies to control the local inflammatory response in BALB/ mice with cutaneous leishmaniasis lesions. Journal of dermatological science, 2018, Volume: 92, Issue:1 Topics: Animals; Antibodies; Antiprotozoal Agents; Cells, Cultured; Dermatitis; Disease Models, Animal; Drug Therapy, Combination; Female; Host-Pathogen Interactions; Imiquimod; Inflammation Mediators; Leishmania major; Leishmaniasis, Cutaneous; Macrophages; Mice, Inbred BALB C; Neutrophil Infiltration; Paromomycin; Skin; Tumor Necrosis Factor-alpha	2018
Efficacy of chitosan, a natural polysaccharide, against Cryptosporidium parvum in vitro and in vivo in neonatal mice. Experimental parasitology, 2018, Volume: 194 Topics: Animals; Animals, Newborn; Antiprotozoal Agents; Caco-2 Cells; Cattle; Cell Line, Tumor; Chitosan; Cryptosporidiosis; Cryptosporidium parvum; Disease Models, Animal; Humans; Intestinal Diseases, Parasitic; Mice; Paromomycin	2018
Curcumin: A promising treatment for Cryptosporidium parvum infection in immunosuppressed BALB/c mice. Experimental parasitology, 2018, Volume: 195 Topics: Animals; Antioxidants; Antiprotozoal Agents; Cattle; Cryptosporidiosis; Cryptosporidium parvum; Curcumin; Disease Models, Animal; Feces; Female; Ileum; Immunosuppression Therapy; Jejunum; Mice; Mice, Inbred BALB C; Microvilli; Oocysts; Oxidants; Paromomycin; Random Allocation	2018
In Vivo Selection of Paromomycin and Miltefosine Resistance in Leishmania donovani and L. infantum in a Syrian Hamster Model. Antimicrobial agents and chemotherapy, 2015, Volume: 59, Issue:8 Topics: Animals; Antiprotozoal Agents; Cricetinae; Disease Models, Animal; Drug Resistance; Female; Leishmania donovani; Leishmania infantum; Leishmaniasis, Visceral; Parasitic Sensitivity Tests; Paromomycin; Phosphorylcholine	2015
Targeted delivery of paromomycin in murine infectious diseases through association to nano lipid systems. Nanomedicine : nanotechnology, biology, and medicine, 2015, Volume: 11, Issue:7 Topics: Animals; Communicable Diseases; Disease Models, Animal; Drug Carriers; Drug Delivery Systems; Humans; Leishmania; Lipids; Liposomes; Mice; Mycobacterium; Paromomycin; Tissue Distribution	2015
The lack of effectiveness of hyperbaric oxygenation as a treatment for Leishmania major in a mouse model. Acta parasitologica, 2015, Volume: 60, Issue:2 Topics: Animals; Antiprotozoal Agents; Benzethonium; Disease Models, Animal; Drug Therapy, Combination; Hyperbaric Oxygenation; Leishmania major; Leishmaniasis, Cutaneous; Mice, Inbred BALB C; Paromomycin; Treatment Outcome	2015
Combined suboptimal schedules of topical paromomycin, meglumine antimoniate and miltefosine to treat experimental infection caused by Leishmania (Viannia) braziliensis. The Journal of antimicrobial chemotherapy, 2015, Volume: 70, Issue:12 Topics: Administration, Oral; Administration, Topical; Animals; Antiprotozoal Agents; Appointments and Schedules; Disease Models, Animal; Drug Therapy, Combination; Injections, Intramuscular; Leishmania braziliensis; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Mesocricetus; Organometallic Compounds; Paromomycin; Phosphorylcholine; Skin; Spleen; Treatment Outcome	2015
Solid lipid nanoparticle loaded with paromomycin: in vivo efficacy against Leishmania tropica infection in BALB/c mice model. Applied microbiology and biotechnology, 2016, Volume: 100, Issue:16 Topics: Animals; Antiprotozoal Agents; Disease Models, Animal; Drug Carriers; Female; Interferon-gamma; Interleukin-4; Leishmania tropica; Leishmaniasis; Mice; Mice, Inbred BALB C; Nanoparticles; Nitric Oxide; Paromomycin; Th1 Cells	2016
Evidence of a drug-specific impact of experimentally selected paromomycin and miltefosine resistance on parasite fitness in Leishmania infantum. The Journal of antimicrobial chemotherapy, 2016, Volume: 71, Issue:7 Topics: Animals; Antiprotozoal Agents; Disease Models, Animal; Drug Resistance; Female; Humans; Leishmania infantum; Leishmaniasis, Visceral; Mice, Inbred BALB C; Paromomycin; Phosphorylcholine; Selection, Genetic; Virulence	2016
Enhanced paromomycin efficacy by solid lipid nanoparticle formulation against Leishmania in mice model. Parasite immunology, 2016, Volume: 38, Issue:10 Topics: Animals; Antiprotozoal Agents; Cytokines; Disease Models, Animal; Drug Carriers; Drug Compounding; Female; Interferon-gamma; Interleukin-4; Leishmania; Leishmaniasis; Lipids; Mice; Mice, Inbred BALB C; Nanoparticles; Nitric Oxide; Paromomycin	2016
Translational bypass of nonsense mutations in zebrafish rep1, pax2.1 and lamb1 highlights a viable therapeutic option for untreatable genetic eye disease. Human molecular genetics, 2008, Dec-15, Volume: 17, Issue:24 Topics: Adaptor Proteins, Signal Transducing; Animals; Chlorocebus aethiops; Codon, Nonsense; COS Cells; Disease Models, Animal; Dose-Response Relationship, Drug; Embryo, Nonmammalian; Eye Diseases, Hereditary; Gene Expression Regulation, Developmental; Gentamicins; Laminin; Paromomycin; PAX2 Transcription Factor; Phenotype; Protein Biosynthesis; Protein Synthesis Inhibitors; Zebrafish; Zebrafish Proteins	2008
Combined topical paromomycin and oral miltefosine treatment of mice experimentally infected with Leishmania (Leishmania) major leads to reduction in both lesion size and systemic parasite burdens. The Journal of antimicrobial chemotherapy, 2009, Volume: 64, Issue:6 Topics: Administration, Oral; Administration, Topical; Animals; Disease Models, Animal; Drug Therapy, Combination; Female; Leishmania major; Leishmaniasis, Cutaneous; Mice; Mice, Inbred BALB C; Paromomycin; Phosphorylcholine; Skin; Spleen; Treatment Outcome	2009
Immunomodulatory effect of picroliv on the efficacy of paromomycin and miltefosine in combination in experimental visceral leishmaniasis. Experimental parasitology, 2011, Volume: 127, Issue:2 Topics: Animals; Antiprotozoal Agents; Cell Proliferation; Cinnamates; Cricetinae; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Glycosides; Leishmania donovani; Leishmaniasis, Visceral; Lymphocytes; Male; Mesocricetus; Paromomycin; Phagocytosis; Phosphorylcholine; Random Allocation; Reactive Nitrogen Species; Reactive Oxygen Species; Vanillic Acid	2011
Genetic reconstruction of protozoan rRNA decoding sites provides a rationale for paromomycin activity against Leishmania and Trypanosoma. PLoS neglected tropical diseases, 2011, Volume: 5, Issue:5 Topics: Animals; Antiprotozoal Agents; Disease Models, Animal; Female; Leishmania; Mice; Parasitic Sensitivity Tests; Paromomycin; Protein Biosynthesis; Recombination, Genetic; RNA, Bacterial; RNA, Protozoan; RNA, Ribosomal; Rodent Diseases; Trypanosoma brucei brucei; Trypanosomiasis, African	2011
Colloidal, in vitro and in vivo anti-leishmanial properties of transfersomes containing paromomycin sulfate in susceptible BALB/c mice. Acta tropica, 2012, Volume: 124, Issue:1 Topics: Administration, Topical; Animals; Antiprotozoal Agents; Chemistry, Pharmaceutical; Disease Models, Animal; Female; Humans; Leishmania major; Leishmaniasis, Cutaneous; Mice; Mice, Inbred BALB C; Parasite Load; Parasitic Sensitivity Tests; Paromomycin; Skin; Spleen; Treatment Outcome	2012
Long-lasting anticryptosporidial activity of nitazoxanide in an immunosuppressed rat model. Folia parasitologica, 2003, Volume: 50, Issue:1 Topics: Adenosine; Animals; Antiprotozoal Agents; Cryptosporidiosis; Cryptosporidium parvum; Disease Models, Animal; Feces; Immunocompromised Host; Male; Nitro Compounds; Parasite Egg Count; Paromomycin; Rats; Rats, Sprague-Dawley; Thiazoles	2003
Efficacy of mangiferin against Cryptosporidium parvum in a neonatal mouse model. Parasitology research, 2006, Volume: 99, Issue:2 Topics: Animals; Animals, Newborn; Animals, Outbred Strains; Antiprotozoal Agents; Cryptosporidiosis; Cryptosporidium parvum; Disease Models, Animal; Female; Humans; Mice; Paromomycin; Treatment Outcome; Xanthones	2006
Immunochemotherapy for cryptosporidiosis in immunosuppressed mouse model. Journal of the Egyptian Society of Parasitology, 2007, Volume: 37, Issue:3 Topics: Animals; Antiprotozoal Agents; Cryptosporidiosis; Disease Models, Animal; Drug Therapy, Combination; Humans; Immunocompromised Host; Immunotherapy; Interferon-gamma; Life Cycle Stages; Mice; Nitro Compounds; Oocysts; Parasite Egg Count; Paromomycin; Random Allocation; Thiazoles; Time Factors; Treatment Outcome	2007
[Experimental study on the action mechanism of paromomycin sulfate as an anticestode agent]. The Japanese journal of antibiotics, 1983, Volume: 36, Issue:3 Topics: Adult; Animals; Child, Preschool; Cricetinae; Diphyllobothriasis; Diphyllobothrium; Disease Models, Animal; Drug Evaluation; Female; Humans; Hymenolepiasis; Hymenolepis; Male; Mice; Middle Aged; Paromomycin	1983
Evaluation of a two-phase scid mouse model preconditioned with anti-interferon-gamma monoclonal antibody for drug testing against Cryptosporidium parvum. The Journal of infectious diseases, 1995, Volume: 172, Issue:4 Topics: Amebicides; Animals; Antibodies, Monoclonal; Cryptosporidiosis; Cryptosporidium parvum; Disease Models, Animal; Drug Evaluation, Preclinical; Evaluation Studies as Topic; Feces; Interferon-gamma; Mice; Mice, SCID; Paromomycin; Weaning	1995
A comparison of anticryptosporidial activity of paromomycin with that of other aminoglycosides and azithromycin in immunosuppressed rats. The Journal of infectious diseases, 1994, Volume: 170, Issue:4 Topics: Animals; Anti-Bacterial Agents; Azithromycin; Cecum; Cryptosporidiosis; Cryptosporidium parvum; Disease Models, Animal; Female; Ileum; Immunosuppression Therapy; Paromomycin; Rats; Rats, Sprague-Dawley	1994
Evaluation of curative anticryptosporidial activity of paromomycin in a dexamethasone-treated rat model. Antimicrobial agents and chemotherapy, 1994, Volume: 38, Issue:7 Topics: Animals; Cryptosporidiosis; Cryptosporidium parvum; Dexamethasone; Disease Models, Animal; Female; Paromomycin; Rats; Rats, Sprague-Dawley	1994
Glycoside antibiotics alone and combined with tetracyclines for prophylaxis of experimental cryptosporidiosis in neonatal BALB/c mice. The Journal of parasitology, 1993, Volume: 79, Issue:4 Topics: Animals; Animals, Newborn; Anti-Bacterial Agents; Azithromycin; Clarithromycin; Cryptosporidiosis; Cryptosporidium parvum; Disease Models, Animal; Doxycycline; Drug Synergism; Drug Therapy, Combination; Erythromycin; Mice; Mice, Inbred BALB C; Minocycline; Paromomycin; Tetracyclines	1993
Evaluation of an animal model system for cryptosporidiosis: therapeutic efficacy of paromomycin and hyperimmune bovine colostrum-immunoglobulin. Clinical and diagnostic laboratory immunology, 1994, Volume: 1, Issue:4 Topics: Animals; Animals, Newborn; Animals, Suckling; Cattle; Colostrum; Cryptosporidiosis; Digestive System; Disease Models, Animal; Evaluation Studies as Topic; Germ-Free Life; Immunoglobulin G; Mice; Mice, SCID; Paromomycin; Swine	1994
Efficacy of aminosidine administered alone or in combination with meglumine antimoniate for the treatment of experimental visceral leishmaniasis caused by Leishmania infantum. The Journal of antimicrobial chemotherapy, 1997, Volume: 40, Issue:2 Topics: Animals; Antiprotozoal Agents; Disease Models, Animal; Drug Therapy, Combination; Female; Leishmania infantum; Leishmaniasis, Visceral; Liver; Meglumine; Meglumine Antimoniate; Mice; Mice, Inbred BALB C; Organometallic Compounds; Paromomycin; Spleen	1997
Comparison of the efficacy of free and non-ionic-surfactant vesicular formulations of paromomycin in a murine model of visceral leishmaniasis. The Journal of pharmacy and pharmacology, 1998, Volume: 50, Issue:12 Topics: Animals; Antiprotozoal Agents; Chemistry, Pharmaceutical; Disease Models, Animal; Drug Delivery Systems; Drug Evaluation, Preclinical; Female; Leishmania donovani; Leishmaniasis, Visceral; Mice; Mice, Inbred BALB C; Paromomycin; Surface-Active Agents; Treatment Outcome	1998
Combined interleukin-12 and topical chemotherapy for established Leishmaniasis drastically reduces tissue parasitism and relapses in susceptible mice. The Journal of infectious diseases, 2001, Jun-01, Volume: 183, Issue:11 Topics: Administration, Cutaneous; Animals; Anti-Bacterial Agents; Antiprotozoal Agents; Disease Models, Animal; Drug Therapy, Combination; Female; Interferon-gamma; Interleukin-12; Interleukin-4; Leishmania major; Leishmaniasis; Mice; Mice, Inbred BALB C; Paromomycin; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger	2001
Leishmania major: bacterial contamination of cutaneous lesions in experimental animals. Israel journal of medical sciences, 1992, Volume: 28, Issue:12 Topics: Animals; Anti-Infective Agents, Local; Bacterial Infections; Benzethonium; Disease Models, Animal; Drug Combinations; Drug Evaluation, Preclinical; Drug Resistance, Microbial; Leishmaniasis, Cutaneous; Macrophages; Male; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Neutrophils; Paromomycin; Time Factors; Treatment Outcome	1992
Therapeutic efficacy of new nitroimidazoles for experimental trichomoniasis, amebiasis, and trypanosomiasis. The American journal of tropical medicine and hygiene, 1970, Volume: 19, Issue:6 Topics: Amebiasis; Animals; Antiprotozoal Agents; Disease Models, Animal; Entamoeba histolytica; Female; Imidazoles; Male; Metronidazole; Mice; Microbial Sensitivity Tests; Nitroso Compounds; Paromomycin; Rats; Stilbamidines; Trichomonas; Trichomonas Infections; Trypanosoma; Trypanosomiasis	1970
Relationship of the enterohepatic cycle to ulcerogenesis in the rat small bowel with flufenamic acid. Gastroenterology, 1970, Volume: 58, Issue:6 Topics: Administration, Oral; Animals; Anti-Inflammatory Agents; Bile Ducts, Intrahepatic; Cholestyramine Resin; Disease Models, Animal; Flufenamic Acid; Fluorine; Injections, Intramuscular; Intestinal Diseases; Intestine, Small; Male; ortho-Aminobenzoates; Paromomycin; Rats; Ulcer	1970